ERBB2 and non-small cell lung carcinoma: Trastuzumab deruxtecan (T-DXd) is currently the first and only ADC approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating adult patients with advanced NSCLC harboring an activating HER2 (ERBB2) mutation [23,24].